Skip to main content
Terug
TECH logo

Bio-Techne Corporation

Datakwaliteit: 100%
TECH
NASDAQ Healthcare Biotechnology
€ 52,00
▲ € 0,52 (1,01%)
Marktkapitalisatie: 8,14B
Dagbereik
€ 51,63 € 53,53
52-Weeksbereik
€ 46,01 € 72,16
Volume
1.585.744
50D / 200D Gem.
€ 60,87 / € 57,62
Vorige Slotkoers
€ 51,48

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 110,8 0,4
P/B 4,2 2,9
ROE % 3,7 3,8
Net Margin % 6,0 3,9
Rev Growth 5Y % 7,0 10,0
D/E 0,2 0,2

Koersdoel Analisten

Hold
€ 69,33 +33.3%
Low: € 62,00 High: € 79,00
Forward K/W
26,2
Forward WPA
€ 1,98
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,2 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 3,15
€ 3,10 – € 3,21
1,7 B 1
FY2029 € 3,03
€ 2,98 – € 3,08
1,5 B 1
FY2028 € 2,52
€ 2,22 – € 2,76
1,4 B 3

Belangrijkste Punten

Revenue grew 6,98% annually over 5 years — modest growth
Earnings declined -56,34% over the past year
ROE of 3,68% is below average
Debt/Equity of 0,23 — conservative balance sheet
Generating 256,55M in free cash flow
P/E of 110,84 — premium valuation

Groei

Revenue Growth (5Y)
6,98%
Revenue (1Y)5,23%
Earnings (1Y)-56,34%
FCF Growth (3Y)8,95%

Kwaliteit

Return on Equity
3,68%
ROIC3,25%
Net Margin6,02%
Op. Margin8,38%

Veiligheid

Debt / Equity
0,23
Current Ratio3,46
Interest Coverage12,02

Waardering

P/E Ratio
110,84
P/B Ratio4,24
EV/EBITDA82,32
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,23% Revenue Growth (3Y) 3,58%
Earnings Growth (1Y) -56,34% Earnings Growth (3Y) -49,27%
Revenue Growth (5Y) 6,98% Earnings Growth (5Y) -14,97%
Profitability
Revenue (TTM) 1,22B Net Income (TTM) 73,40M
ROE 3,68% ROA 2,87%
Gross Margin 64,80% Operating Margin 8,38%
Net Margin 6,02% Free Cash Flow (TTM) 256,55M
ROIC 3,25% FCF Growth (3Y) 8,95%
Safety
Debt / Equity 0,23 Current Ratio 3,46
Interest Coverage 12,02 Dividend Yield 0,01%
Valuation
P/E Ratio 110,84 P/B Ratio 4,24
P/S Ratio 6,67 PEG Ratio -1,97
EV/EBITDA 82,32 Dividend Yield 0,01%
Market Cap 8,14B Enterprise Value 8,42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,22B 1,16B 1,14B 1,11B 931,03M
Net Income 73,40M 168,11M 285,26M 272,05M 140,41M
EPS (Diluted) 0,46 1,05 1,76 1,66 0,87
Gross Profit 790,27M 769,73M 769,82M 756,50M 632,85M
Operating Income 102,26M 206,69M 298,94M 296,59M 237,30M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,56B 2,70B 2,64B 2,29B 2,26B
Total Liabilities 639,06M 635,02M 672,18M 593,79M 691,72M
Shareholders' Equity 1,92B 2,07B 1,97B 1,70B 1,56B
Total Debt 444,06M 419,54M 454,97M 325,97M 420,55M
Cash & Equivalents 162,19M 151,79M 180,57M 172,57M 199,09M
Current Assets 608,30M 617,42M 621,48M 605,56M 510,61M
Current Liabilities 175,85M 159,38M 128,51M 176,02M 152,28M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#860 of 1024
28

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026